Motherisk update: Counseling pregnant women treated with paroxetine. Concern about cardiac malformations

Canadian Family Physician

Volumn 52, Issue MAY, 2006, Pages 593-594

  Einarson, Adrienne ^a   Koren, Gideon ^a  

^a Motherisk Program   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PAROXETINE; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; CARDIOVASCULAR MALFORMATION; CONGENITAL MALFORMATION; DEPRESSION; DISEASE ASSOCIATION; FEMALE; FIRST TRIMESTER PREGNANCY; HEART VENTRICLE SEPTUM DEFECT; HUMAN; MATERNAL CARE; PREDICTION; PREGNANCY; PRENATAL DRUG EXPOSURE; PUBLISHING; PUERPERAL DEPRESSION; CANADA; CHEMICALLY INDUCED DISORDER; CONGENITAL HEART MALFORMATION; PRACTICE GUIDELINE; PREGNANCY COMPLICATION; RISK;

CANADA; DEPRESSIVE DISORDER; FEMALE; HEART DEFECTS, CONGENITAL; HUMANS; PAROXETINE; PRACTICE GUIDELINES; PREGNANCY; PREGNANCY COMPLICATIONS; RISK; SEROTONIN UPTAKE INHIBITORS;

EID: 33745216461     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Einarson TR, Einarson A. Newer antidepressants in pregnancy and rates of maj or malformations: a meta-analysis of prospective comparative studies. Pharmacoepidemiol Drug Saf 2005;14(12):823-7.
2. GlaxoSmithKline. Nav safety information regarding paroxetine: findings suggest increased risk over other antidepressants, of congenital malformations, following first trimester exposure to paroxetine. GSK advisory September 2005. Mississauga, Ont: GlaxoSmithKline; 2005. Available at: http://www.gsk.ca/en/health_info/ PAXIL_PregnancyDHCPL_E-V4.pdf. Accessed 2006 March 23.
3. GlaxoSmithKline. Health Canada endorsed important safety information on Plaxil (paroxetine) and possible increased risk of birth defects. Health Canada advisory October 2005. Ottawa, Ont: Health Canada; 2005. Available at: http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/ 2005/paxil_3_hpc-cps_e.html. Accessed 2006 March 23.
4. Alwan S, Reethuis J, Rasmussen S, Olney R, Friedman JM, Maternal use of selective serotonin re-uptake inhibitors and risk for birth defects [abstractl, Birth Defects Res A Clin Mol Teratol 2005;73:291.
5. Wolgelius P, Norgaard M, Muff E, Mortensen PB, Lipworth L, Sorensen HT. Maternal use of selective serotonin reuptake inhibitors and risk of adverse pregnancy outcomes [abstract]. Pharmacoepidemiol Drug Saf 2005;14:S72.
6. Diav-Citrin O, Shachtman S, Weinbaum D, Amon J, Gianantonio E, Clementi M, et al. Pregnancy outcome after gestation exposure to paroxetine: a prospective controlled cohort study. Presented at the Teratology Society 45th Annual Meeting; 2005 June 25-30; St. Pete Beach, Fla.
7. Briggs G, Freeman P, Yaffe S. Drug in pregnancy and lactation. 7th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2005. p. 553.
8. Ericson A, Kallen B, Wilholm BE. Delivery outcome after the use of antidepressants in early pregnancy. Eur J Clin Pharmacol 1999;56:503-8.
9. Kulin NA, Pastuszak A, Sage S, Schick-Boschetto B, Spive G, Feldkamp M, et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors a prospective controlled multicenter study. JAMA 1998;279:609-10.
10. Kallen BA, Otterblad Olausson P. Maternal drug use in early pregnancy and infant cardiovascular defects. Reprod Toxicol 2003; 7:255-61.
11. Beck CT. Postpartum depression predictors inventory (revised). Adv Neonat Care 2003:3(1):47-8.
12. Einarson A, Selby P, Koren G. Abrupt discontinuation of psychotropic drugs during pregnancy: fear of teratogenic risk and impact of counseling. J Psychiatry Neurosci 2001;26(1):44-8.